Eli Lilly and Co's Zepbound (Tirzepatide) Injection is Now Available in US Pharmacies for Adults Living with Obesity, Effective December 15 Zepbound Will Be Added To Cigna Healthcare's Commercial Formularies
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly and Co announced that its Zepbound (tirzepatide) injection is now available in US pharmacies for adults with obesity or overweight with weight-related medical problems. Following FDA approval on Nov. 8, 2023, Zepbound will be added to Cigna Healthcare's commercial formularies effective December 15. Zepbound is available in six doses and should be used with a reduced-calorie diet and increased physical activity, but not with other tirzepatide-containing products or GLP-1 receptor agonist medicines.
December 05, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Zepbound is now available for prescription, which could lead to increased sales and revenue for the company.
The availability of Zepbound in pharmacies and its addition to Cigna's formularies is likely to increase its accessibility and usage, potentially leading to higher sales and positive impact on Eli Lilly's revenue in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100